Chemotherapy in Head and Neck Cancer Clinical Predictors of Tolerance and Outcomes

被引:12
|
作者
Kubicek, Gregory J. [1 ]
Kimler, Bruce F. [2 ]
Wang, Fen [2 ]
Reddy, Eashwer K. [2 ]
Girod, Douglas A. [3 ]
Williamson, Steven K. [4 ]
机构
[1] Univ Pittsburgh, Med Ctr, Dept Radiat Oncol, Pittsburgh, PA USA
[2] Univ Kansas, Med Ctr, Dept Radiat Oncol, Kansas City, KS 66103 USA
[3] Univ Kansas, Med Ctr, Dept Otolaryngol, Kansas City, KS 66103 USA
[4] Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66103 USA
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2011年 / 34卷 / 04期
关键词
head and neck cancer; chemotherapy; capsulation; tolerance; SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; RADIATION-THERAPY; CONCURRENT CHEMOTHERAPY; RANDOMIZED TRIAL; RADIOTHERAPY; CISPLATIN; CHEMORADIOTHERAPY; CARBOPLATIN; TIME;
D O I
10.1097/COC.0b013e3181e9c0a2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The addition of chemotherapy is more efficacious than radiation alone in the treatment of head and neck cancer (HNC). However, little data are available regarding the best chemotherapy agent and dosing, or factors associated with chemotherapy compliance. Methods: Retrospective review of all HNC patients receiving combined chemotherapy and radiotherapy at the University of Kansas Medical Center between 1994 and 2006. A total of 172 patients were analyzed in this report. Results: A total of 37% of patients were able to complete the entire chemotherapy regimen as intended. Multiple factors were examined in relation to chemotherapy completion and clinical outcome. Factors associated with not being able to complete chemotherapy on Cox regression analysis include use of a platinum agent and older age at diagnosis. No chemotherapy-related variables were prognostic for overall survival or disease-free survival. Conclusion: Factors associated with reduced chemotherapy compliance include older age and cisplatin agent. None of the chemotherapy characteristics (agent, total dose, and schedule) were associated with outcome.
引用
收藏
页码:380 / 384
页数:5
相关论文
共 50 条
  • [31] Hyperfractionated Radiotherapy with Concurrent Docetaxel for Advanced Head and Neck Cancer: A Phase II Study
    Karasawa, Kumiko
    Matsumoto, Fumihiko
    Ito, Sin
    Oba, Sinichi
    Furuya, Tomohisa
    Hirowatari, Hisako
    Izawa, Hiromi
    Ito, Kana
    Sasai, Keisuke
    ANTICANCER RESEARCH, 2012, 32 (09) : 4013 - 4018
  • [32] Systemic therapy in the curative treatment of head-and-neck squamous cell cancer: Cancer Care Ontario clinical practice guideline
    Winquist, E.
    Agbassi, C.
    Meyers, B. M.
    Yoo, J.
    Chan, K. K. W.
    CURRENT ONCOLOGY, 2017, 24 (02) : E157 - E162
  • [33] Addition of chemotherapy to hyperfractionated radiotherapy in advanced head and neck cancer-a meta-analysis
    Haussmann, Jan
    Tamaskovics, Balint
    Boelke, Edwin
    Djiepmo-Njanang, Freddy-Joel
    Kammers, Kai
    Corradini, Stefanie
    Hautmann, Matthias
    Ghadjar, Pirus
    Maas, Kitti
    Schuler, Patrick J.
    Hoffmann, Thomas K.
    Lammering, Guido
    Budach, Wilfried
    Matuschek, Christiane
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (12) : 1041 - 1049
  • [35] CLINICAL PRACTICE GUIDANCE FOR RADIOTHERAPY PLANNING AFTER INDUCTION CHEMOTHERAPY IN LOCOREGIONALLY ADVANCED HEAD-AND-NECK CANCER
    Salama, Joseph K.
    Haddad, Robert I.
    Kies, Merril S.
    Busse, Paul M.
    Dong, Lei
    Brizel, David M.
    Eisbruch, Avraham
    Tishler, Roy B.
    Trotti, Andy M.
    Garden, Adam S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : 725 - 733
  • [36] Systemic chemotherapy for squamous cell head and neck cancer
    Adelstein, DJ
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (12) : 2151 - 2163
  • [37] A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer
    Rades, Dirk
    Zwaan, Inga
    Idel, Christian
    Pries, Ralph
    Bruchhage, Karl L. L.
    Hakim, Samer G. G.
    Yu, Nathan Y. Y.
    Soror, Tamer
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (07):
  • [38] Induction chemotherapy for locally advanced head and neck cancer
    Calais, G.
    Chapet, S.
    Ruffier-Loubiere, A.
    Bernadou, G.
    CANCER RADIOTHERAPIE, 2013, 17 (5-6): : 498 - 501
  • [39] Induction chemotherapy for head and neck cancer: is there still a role?
    Ove, Roger
    Nabell, Lisle M.
    FUTURE ONCOLOGY, 2016, 12 (13) : 1595 - 1608
  • [40] Survival benefit of post-operative chemotherapy for intermediate-risk advanced stage head and neck cancer differs with patient age
    Chen, Michelle M.
    Colevas, A. Dimitrios
    Megwalu, Uchechukwu
    Divi, Vasu
    ORAL ONCOLOGY, 2018, 84 : 71 - 75